Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results.
Bichoupan K, Tandon N, Crismale JF, Hartman J, Del Bello D, Patel N, Chekuri S, Harty A, Ng M, Sigel KM, Bansal MB, Grewal P, Chang CY, Leong J, Im GY, Liu LU, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Dieterich DT, Branch AD. Bichoupan K, et al. World J Virol. 2017 Nov 12;6(4):59-72. doi: 10.5501/wjv.v6.i4.59. World J Virol. 2017. PMID: 29147645 Free PMC article.
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.
Crismale JF, Martel-Laferrière V, Bichoupan K, Schonfeld E, Pappas A, Wyatt C, Odin JA, Liu LU, Schiano TD, Perumalswami PV, Bansal M, Dieterich DT, Branch AD. Crismale JF, et al. Among authors: bichoupan k. Liver Int. 2014 Aug;34(7):1018-24. doi: 10.1111/liv.12342. Epub 2013 Oct 25. Liver Int. 2014. PMID: 24118693 Free PMC article.
Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir.
Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF. Bichoupan K, et al. Aliment Pharmacol Ther. 2014 Jan;39(2):209-16. doi: 10.1111/apt.12560. Epub 2013 Nov 24. Aliment Pharmacol Ther. 2014. PMID: 24266536 Free PMC article.
Commentary: real-world triple therapy experience treating hepatitis C virus - authors' reply.
Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF. Bichoupan K, et al. Aliment Pharmacol Ther. 2014 Mar;39(5):543. doi: 10.1111/apt.12641. Aliment Pharmacol Ther. 2014. PMID: 24494843 No abstract available.
Telaprevir activity in treatment-naive patients infected with hepatitis C virus genotype 4.
Sefcik RK, Bichoupan K, Martel-Laferrière V, Odin JA, Liu LU, Perumalswami P, Bansal M, Dieterich DT, Ahmad J, Schiano TD, Branch AD. Sefcik RK, et al. Among authors: bichoupan k. J Infect Dis. 2014 Dec 1;210(11):1855-6. doi: 10.1093/infdis/jiu360. Epub 2014 Jun 26. J Infect Dis. 2014. PMID: 24970848 Free PMC article. No abstract available.
28 results